Ciloa will be presenting its disrupting co-agonist, Adiponectin, that boosts all GLP-1RA therapeutic effects on obesity/diabetes/MASH @Swiss Biotech Days 2024 (Basel, April 22-23)
Ciloa, a preclinical stage French biotechnology company with a unique exosome bioengineering technology will attend the SwissBiotechDay 2024. Ciloa will be presenting…
Read More